# ORIGINAL SCIENTIFIC REPORTS



# **Outcome Analysis of Blood Product Transfusion in Trauma** Patients: A Prospective, Risk-Adjusted Study

Grant V. Bochicchio · Lena Napolitano · Manjari Joshi · Kelly Bochicchio · Walter Meyer · Thomas M. Scalea

Published online: 24 June 2008

© Société Internationale de Chirurgie 2008

#### Abstract

Background Studies have confirmed adverse outcome associated with transfusion of packed red blood cells (PRBCs) in trauma; however, little data are available regarding other blood product transfusion, such as fresh frozen plasma (FFP) and platelets. The objective of this study was to examine risk-adjusted outcome in trauma with stratification by blood product type.

Methods Prospective data were collected daily for 1,172 consecutive trauma patients admitted to the intensive care unit (ICU) during a 2-year period, including transfusion rates of blood products (PRBCs, FFP, platelets). Outcome assessment included infection rate, ventilator days (Vdays), ICU and hospital length of stay (LOS), and mortality.

Results Blood products were transfused in 786 (67%) patients. The study cohort had a mean age of 43  $\pm$  21 years and Injury Severity Score (ISS) of  $24 \pm 13$ . Although the majority of patients were men, women were more likely to be transfused (p < 0.001). Mean transfusion rates of PRBCs  $(5.5 \pm 9.6 \text{ U})$ , FFP  $(5.4 \pm 11.4)$ , and platelets  $(3.7 \pm 11.1)$ were high. Univariate analysis identified that blood product

Presented, in part, at the meeting of the American Association for the Surgery of Trauma, Minneapolis, Minnesota, Sept 12–15, 2003.

G. V. Bochicchio ( ) · L. Napolitano · T. M. Scalea R. Adams Cowley Shock Trauma Center Programs in Trauma,

22 South Greene Street, Baltimore, MD 21201, USA

e-mail: gbochicchio@umm.edu

M. Joshi · K. Bochicchio R. Adams Cowley Shock Trauma Center Programs in Infectious Disease, Baltimore, MD, USA

Department of Epidemiology, University of Maryland School of Medicine, Baltimore, MD, USA

transfusion (any type) was associated with a significantly greater infection rate (34% vs. 9.4%; p < 0.001), hospital LOS (18.6 vs. 9 days; p < 0.001), ICU LOS (13.7 vs. 7.4 days; p < 0.001), Vdays (12.9 vs. 6.3 days; p < 0.001), and mortality (19% vs. 8.3%; p < 0.001). Multivariate analysis (risk-adjusted for severity of injury by ISS, age, sex, and race, and stratified by blood product type) confirmed that risk of infection increased by 5%, and hospital LOS, ICU LOS, and Vdays increased by 0.64, 0.42, and 0.47 days, respectively, for every unit of PRBCs given. Risk of death increased by 3.5% for every unit of FFP transfused.

Conclusion There is a dose-dependent correlation between blood product transfusion and adverse outcome (increased mortality and infection) in trauma patients.

## Introduction

Blood transfusion is a major component in the treatment of acute traumatic hemorrhagic shock. Early use of blood transfusion in resuscitation protocols for acute trauma is advocated in the Advanced Trauma Life Support guidelines of the American College of Surgeons [1]. However, recent literature has documented severe immunologic responses to blood transfusion with resultant adverse outcomes [2, 3]. Transfusion of blood products, including shed blood, also has been found to be associated with deleterious effects on the immune system [4–8]. At the cellular level, immune cell proliferation is altered with significant effects on T-cellrelated immunity and cytokine immunomodulation. Recently, inflammatory cytokine release has been shown to be amplified with the transfusion of old stored blood [9].

In trauma patients, blood transfusion has been confirmed as an independent risk factor for death, perioperative



infection, postinjury multiple organ failure, systemic inflammatory response syndrome, and admission to the intensive care unit (ICU) [10–15]. The association of blood transfusion with immunosuppression, hyperinflammation, and adverse outcome has led some to advocate caution for the liberal use of blood transfusion in injured patients [16].

The majority of research in the trauma population related to the transfusion of blood products has focused on the transfusion of packed red blood cells (PRBCs). To our knowledge, no previous studies have evaluated the impact of concurrent transfusion of specific individual blood component therapy (PRBCs, fresh frozen plasma (FFP), platelets) on trauma outcome. Thus, the goal of this study was to examine risk-adjusted outcome in trauma with stratification of transfusions by blood product type.

### Materials and methods

Prospective (independent of trauma-registry) data were collected daily by a single individual on 1,172 consecutive trauma patients admitted >48 hours to the ICU at the R. Adams Cowley Shock Trauma Center during a 2-year period (2002-2004). Patients were stratified by age, sex, race, Glasgow Coma Score (GCS) score, and Injury Severity Score (ISS). The transfusion of individual blood product types (PRBCs in units, FFP in units, and platelets in equivalent units) were calculated daily. Transfusion of blood products was determined by the trauma or ICU team based on clinical grounds. No formal transfusion protocol for blood products was used. In addition, no specific protocol to transfuse leukocyte-reduced or plasma-reduced products was used. Admission base deficit, serum lactate, and shock index (HR/SBP) were collected as measures of shock severity.

Outcome was assessed by infection rate, ventilator days, ICU and hospital length of stay (LOS), and mortality. CDC definitions for infection were used to diagnose infection. Categorical variables were compared by using Pearson's  $\chi^2$  and contingency table analysis. Multiple logistic regression analyses were used for binary outcomes, using the covariates age, sex, race, and ISS as adjusters. The blood product

variables (measured in number of units transfused) were entered into the regression equation so that the variance in outcome explained by these variables would be partialled out of the final model, thus allowing interpretation of the blood product of interest to be made independent of the effects of the other blood products. Continuous variables were compared by using Student's *t* test (to compare differences between transfused and nontransfused patients) and multiple linear regression analysis, using the same covariates as adjusters (Stata, Release 6.0, Stata Corp., College Station, TX).

### Results

Demographics and blood product transfusion

The study cohort consisted of 873 men (74%) and 299 women (26%). The mean age of the study cohort was  $43 \pm 21$  years with a mean Injury Severity Score (ISS) of  $24 \pm 13$  (Table 1). Blunt trauma accounted for the majority of the injuries (n = 914, 78%). Blood products were transfused in 786 (67%) of the 1,172 patients with majority (88%) occurring during the first 48 hours of admission. Although the majority of the patients were men, women were more likely to be transfused (p < 0.001; Table 1).

Most patients (n=480, 61%) received combination transfusion therapy, with more than one blood product type transfused. Transfusion of PRBCs only (n=246), FFP only (n=56), or platelets only (n=4) was less common. The mean number of units transfused by product type was as follows: PRBCs =  $5.5 \pm 9.6$  U, FFP =  $5.4 \pm 11.4$  U, and platelets =  $3.7 \pm 11.1$  equivalent units (Table 2).

Factors associated with blood product use

Trauma patients who received blood product transfusion had significantly higher mean ISS (p < 0.001, Table 1), lower admission hematocrit, lower admission platelet count, higher admission INR, increased lactate, increased shock index, and lower RTS and admission GCS (Table 3). Logistic regression analysis (adjusted for age, ISS, GCS,

Table 1 Admission characteristics and blood product transfusion

|                              | Total $(n = 1,172)$ | Blood product transfusion $(n = 786)$ | No blood product transfusion $(n = 386)$ | p value         |
|------------------------------|---------------------|---------------------------------------|--|-----------------|
| Age (year)                   | 43 ± 21             | $43 \pm 21$                           | $42 \pm 20$                              | NS              |
| Male                         | 873                 | 562 (64%)                             | 311 (36%)                                |                 |
| Female                       | 299                 | 224 (75%)                             | 75 (25%)                                 | <0.001 vs. male |
| Injury Severity Score        | $24 \pm 13$         | $27 \pm 13$                           | $19 \pm 11$                              | < 0.001         |
| Admission Glasgow Coma Score | $12 \pm 5$          | $11 \pm 5$                            | $12.5 \pm 4$                             | NS              |

NS, not significant



**Table 2** Blood component utilization in trauma (n = 786 patients)

| Blood product type      | Units transfused            | Patients<br>transfused |
|-------------------------|-----------------------------|------------------------|
| Transfusion combination | NA                          | 480 (61.1)             |
| PRBCs only              | $5.5 \pm 9.6 \text{ U}$     | 246 (31.3)             |
| FFP only                | $5.4 \pm 11.4 \text{ U}$    | 56 (7.1)               |
| Platelets only          | $3.7 \pm 11.1$ equivalent U | 4 (0.5)                |

PRBCs, packed red blood cells; FFP, fresh frozen plasma Data are mean  $\pm$  SD or number (%)

and all other variables present in the model) confirmed age, ISS, shock index, lactate, hematocrit, INR, and platelet count as independent predictors of blood product transfusion (Table 4).

## Blood product use and outcome

Transfused patients had a significantly greater infection rate, hospital and ICU length of stay, ventilator days, and hospital mortality (Table 5). The most common type of infection was respiratory, followed by genitourinary, blood, intra-abdominal, and skin/wound (Fig. 1). When analyzed by multivariate logistic regression analysis, risk of infection and mortality increased significantly for every unit of PRBCs or FFP transfused (Table 6). Transfusion of PRBCs and FFP were associated with increased hospital and ICU length of stay. In contrast, transfusion of platelets did not adversely impact mortality and infection risk, after controlling for the transfusion of PRBCs and FFP in addition to age, GCS, and ISS.

#### Discussion

The impact of PRBC transfusion on outcome in the critically ill and injured patients has undergone intense investigation recently, but many of these studies are limited by retrospective data collection efforts and lack of evaluation of transfusion of other blood product types. To our knowledge, the current prospective study represents the

**Table 3** Admission variables stratified by blood product transfusion vs. no blood product transfusion ( $\chi^2$  analysis)

| Blood product transfusion $(n = 786)$       | No blood product transfusion ( $n = 386$ )   | p value   |
|---|--|---|
| 29 ± 8                                      | 37 ± 7   | <0.001  |
| $1.8 \pm 1$                                 | $1.1 \pm 0.09$   | < 0.001   |
| $80 \text{ k} \pm 38 \text{ K/}\mu\text{l}$ | $148 \text{ k} \pm 77 \text{ K/}\mu\text{l}$   | < 0.001   |
| $6.1 \pm 4 \text{ mmol/l}$                  | $3.2 \pm 2 \text{ mmol/l}$   | < 0.001   |
| $0.9 \pm 0.5$                               | $0.6 \pm 0.3$  | < 0.001   |
| $6.6 \pm 1.5$                               | $7.2 \pm 1.1$  | < 0.001   |
| $11 \pm 4.7$                                | $12.5 \pm 4$   | < 0.001   |
|   | transfusion $(n = 786)$<br>$29 \pm 8$<br>$1.8 \pm 1$<br>$80 \text{ k} \pm 38 \text{ K/µl}$<br>$6.1 \pm 4 \text{ mmol/l}$<br>$0.9 \pm 0.5$<br>$6.6 \pm 1.5$ | transfusion $(n = 786)$ transfusion $(n = 386)$ $29 \pm 8$ $37 \pm 7$ $1.8 \pm 1$ $1.1 \pm 0.09$ $80 \text{ k} \pm 38 \text{ K/µl}$ $148 \text{ k} \pm 77 \text{ K/µl}$ $6.1 \pm 4 \text{ mmol/l}$ $3.2 \pm 2 \text{ mmol/l}$ $0.9 \pm 0.5$ $0.6 \pm 0.3$ $6.6 \pm 1.5$ $7.2 \pm 1.1$ |

Table 4 Risk factors for blood product transfusion in trauma patients

| Variable                 | OR   | 95% CI      | p value |
|--------------------------|------|-------------|---------|
| Age (year)               | 1.03 | (1.01–1.06) | < 0.001 |
| ISS                      | 1.2  | (1.02-1.31) | < 0.001 |
| Shock index              | 2.6  | (1.98-2.83) | < 0.001 |
| Admission lactate        | 1.7  | (1.57-1.87) | < 0.001 |
| Admission Hct            | 5.6  | (4.5–5.88)  | < 0.001 |
| Admission INR            | 4.8  | (4.3–5.2)   | < 0.001 |
| Admission platelet Count | 4.1  | (3.8–4.4)   | < 0.001 |
|                          |      |             |         |

Multiple logistic regression analysis. Odds ratios were adjusted for all other variables present in the model


**Table 5** Outcome analysis stratified by blood product transfusion versus no transfusion

|                    | Blood product transfusion $(n = 786)$ | No blood product transfusion $(n = 386)$ | p value |
|--------------------|---------------------------------------|--|---------|
| Infection          | 230 (34%)                             | 46 (9.4%)                                | < 0.001 |
| Ventilator days    | $12.9 \pm 12$                         | $6.3 \pm 6$                              | < 0.001 |
| Hospital days      | $18.6 \pm 14$                         | $9 \pm 7$                                | < 0.001 |
| ICU days           | $13.7 \pm 11$                         | $7 \pm 5$                                | < 0.001 |
| ICU admission      | 724 (74%)                             | 249 (26%)                                | < 0.001 |
| Hospital mortality | 147 (21.4%)                           | 32 (6.5%)                                | < 0.001 |

first evaluation of the impact of blood product type (PRBCs, FFP, platelets) on outcome in the critically injured patient. This prospective study adds to the literature that transfusion of PRBCs and/or FFP are both associated with increased risk for mortality and infection, after controlling for numerous variables that affect trauma outcome. The authors realize the limitations of ISS as the principal injury severity scale; however, this score was used because it remains the standard in the majority of trauma studies.

PRBC transfusion has been confirmed an independent risk factor for death, perioperative infection, systemic inflammatory response syndrome, postinjury multiple organ failure, and admission to the ICU [10–14]. Blood transfusion within 24 hours of trauma admission (n = 9,539) was confirmed as a significant independent predictor of





**Fig. 1** Incidence of infection in transfused patients stratified by site (n = 230)

mortality, ICU admission, and ICU length of stay after stratification for ISS, GCS, and age by logistic regression analysis [15]. An additional study using a larger cohort (n = 15,534) and stratification for other variables that affect trauma outcome, including sex, race, and admission shock variables (admission base deficit, serum lactate, and shock index [HR/SBP]) also confirmed that blood transfusion was an independent predictor of mortality, ICU admission, ICU LOS, and hospital LOS in trauma [16].

Similarly, blood transfusion has been identified a strong independent predictor of mortality and hospital length of stay in patients with blunt liver and spleen injuries after controlling for indices of shock and injury severity [17]. Transfusion-associated mortality risk was highest in the subset of patients managed nonoperatively, and these authors recommended prospective examination of transfusion practices in treatment algorithms of solid organ injury.

Recently, Hill and colleagues performed a meta-analysis of 20 peer-reviewed articles published from 1986 to 2000 in which criteria for inclusion was defined as a control group (nontransfused) compared with a treated (transfused) group (total, n=13,152) [18]. The effect of blood transfusion in trauma patients compared with other surgical patients was examined in a separate meta-analysis. The common odds ratio for all articles evaluating the incidence of postoperative bacterial infection was 3.45 with 17 of 20 studies demonstrating statistical significance. The common odds ratio for the subgroup of trauma patients was 5.26

with all studies showing a value of p < 0.05 (0.005 to 0.0001), confirming that allogenic blood transfusion was found to be a greater risk factor for the development of postoperative bacterial infection in the trauma patient compared with the elective surgical patient.

These data confirm that blood transfusion is associated with significant risk for increased mortality and infection after trauma, and this current study confirms these findings as well. These data suggest that we institute all efforts to reduce blood transfusion in trauma patients. Because blood transfusion is the only current therapy available for the treatment of hemorrhagic shock, other than crystalloid resuscitation, our efforts should focus on limitation of blood transfusion for the treatment of anemia in hemodynamically stable critically ill trauma patients.

A recent post-hoc cohort analysis of the trauma patient population from the prospective multicenter, randomized, controlled trial, Transfusion Requirements in Critical Care Trial (TRICC), was reported [19]. This study compared the use of restrictive and liberal transfusion strategies in resuscitated critically ill trauma patients with anemia. Critically ill trauma patients with a hemoglobin concentration <9 g/dl within 72 hours of admission to the ICU were randomized to a restrictive (hemoglobin concentration, 7 g/dl) or liberal (hemoglobin concentration, 10 g/dl) red blood cell transfusion strategy. The mean units of PRBCs transfused per patient (2.3  $\pm$  4.4 vs. 5.4  $\pm$  4.3; p < 0.0001) were significantly lower in the restrictive group than in the liberal group. The 30-day all-cause mortality rates in the restrictive group were 10% compared with 9% in the liberal group (p = 0.81). These data confirm that a restrictive red blood cell transfusion strategy seems to be safe for critically ill multiple-trauma patients. A randomized, controlled trial would provide the appropriate level of evidence with regard to the daily use of blood in this population of patients.

Similarly, a prospective multicenter observational study in 3,534 patients from 146 western European ICUs confirmed the common occurrence of anemia and the large use of blood transfusions in critically ill patients [20]. Additionally, this epidemiologic study provided evidence of an association between blood transfusions and increased mortality by using

Table 6 Risk of infection, hospital and ICU LOS, and mortality stratified by blood product type (adjusted for age, ISS, and admission GCS)

|              | PRBCs OR (CI)     | FFP OR (CI)       | Platelets OR (CI)                   |
|--------------|-------------------|-------------------|-------------------------------------|
| Infection    | 2.8 (1.96–3.94)*  | 1.02 (1.01–1.04)* | 0.94 (0.96–1)                       |
| Hospital LOS | 8.1 (6.6–9.03)*   | 1.3 (1.3–1.41)*   | $-0.15 (-0.023 \text{ to } 0.07)^*$ |
| ICU LOS      | 5.6 (4.2–7.06)*   | 1.25 (1.2–1.31)*  | $-0.08 (-0.14 \text{ to } 0.01)^*$  |
| Mortality    | 1.05 (1.03–1.07)* | 1.03 (1.02–1.05)* | 1.03 (1.02–1.04)                    |

<sup>\*</sup> p < 0.001

LOS, length of stay; ICU, intensive care unit; PRBCs, packed red blood cells; FFP, fresh frozen plasma; OR, odds ratio; CI, confidence interval



a matched cohort propensity analysis, with 28-day mortality rate 22.7% among patients with blood transfusions and 17.1% among those without (p = 0.02), with confirmation by the Kaplan-Meier log-rank test.

A prospective, multicenter, observational, cohort study (CRIT trial) performed in the United States also confirmed that the number of PRBC transfusions a patient received was independently associated with increased mortality and longer ICU and hospital LOS [21].

A post-hoc cohort analysis of all trauma patients enrolled in the U.S. CRIT trial confirmed that 55.4% of all trauma patients were transfused with a mean of  $5.8 \pm 5.5$  units during the ICU stay [22]. Compared with the full study population, patients in the trauma subset were more likely to be transfused and received an average of 1 additional unit of blood. This current prospective study documents similar findings regarding PRBC utilization in trauma, but with a much wider range  $(5.5 \pm 9.6$  units PRBCs). Importantly, this prospective study also provides additional data regarding the utilization of other blood products (FFP, platelets) in trauma and its impact on outcome.

#### Conclusion

There is a dose dependent correlation between blood product transfusion (PRBCs, FFP) and adverse outcome (mortality, infection) in critically ill trauma patients after appropriate stratification for all other variables that affect trauma outcome. All efforts to reduce blood transfusion in critically ill trauma patients should be implemented.

## References

- American College of Surgeons, Committee on Trauma (1997)
   Advanced trauma life support program for physicians manual, 6th edn. American College of Surgeons, Chicago
- Dzik S, Blajchman MA, Blumberg N et al (1996) Current research on the immunomodulatory effect of allogeneic blood transfusion. Vox Sang 70:187–194
- 3. Innerhofer P, Luz G, Spotl L et al (1999) Immunologic changes after transfusion of buffy coat-poor versus white cell-reduced blood to patients undergoing arthroplasty. Transfusion 39:1089–1096
- Bengtsson A, Avall A, Hyllner M, Bengtson JP (1998) Formation of compliment split products and pro-inflammatory cytokines by reinfusion of shed autologous blood. Toxicol Lett 100–101:129–133
- Fransen E, Maessen J, Senden N et al (1999) Impact of blood transfusions on inflammatory mediator release in patients undergoing cardiac surgery. Chest 116:1233–1239
- Avall A, Hyllner M, Bengston JP et al (1997) Postoperative inflammatory response after autologous and allogeneic blood transfusion. Anesthesiology 87:511–516

- Schmidt H, Bendtzen K, Mortensen PE (1998) The inflammatory cytokine response after autotransfusion of shed mediastinal blood. Acta Anaesthesiol Scand 42:558–564
- Haynes SL, Wong JC, Torella F, Dalrymple K, Pilsworth L, McCollum CN (2001) The influence of homologous blood transfusion on immunity and clinical outcome in aortic surgery. Eur J Vasc Endovasc Surg 22:244–250
- Zallen G, Moore EE, Ciesla DJ et al (2000) Stored red blood cells selectively activate human neutrophils to release IL-8 and secretory PLA-2. Shock 13:29–33
- Carson JL, Altman DG, Duff A et al (1999) Risk of bacterial infection associated with allogeneic blood transfusion among patients undergoing hip fracture repair. Transfusion 39:694–700
- Taylor RW, Manganaro LA, O'Brien JA et al (2002) Impact of allogeneic packed red blood cell transfusion on nosocomial infection rates in the critically ill patient. Crit Care Med 30: 2249–2254
- Claridge JA, Sawyer RG, Schulman AM et al (2002) Blood transfusion correlate with infections in trauma patients in a dosedependent manner. Am Surg 68:566–572
- Moore FA, Moore EE, Sauaia A (1997) Blood transfusion: an independent risk factor for postinjury multiple organ failure. Arch Surg 132:620–625
- Dunne JR, Malone DL, Tracy JK, Napolitano LM (2004) Allogenic blood transfusion in the first 24 hours after trauma is associated with increased systemic inflammatory response syndrome (SIRS) and death. Surg Infect (Larchmt) 5:395–404
- Malone DL, Dunne J, Tracy JK, Putnam AT, Scalea TM, Napolitano LM (2003) Blood transfusion, independent of shock severity, is associated with worse outcome in trauma. J Trauma 54:898–905
- Silliman CC, Moore EE, Johnson JL, Gonzalez RJ, Biffl WL (2004) Transfusion of the injured patient: proceed with caution. Shock 21:291–299
- Robinson WP III, Ahn J, Stiffler A, Rutherford EJ, Hurd H, Zarzaur BL, Baker CC, Meyer AA, Rich PB (2005) Blood transfusion is an independent predictor of increased mortality in nonoperatively managed blunt hepatic and splenic injuries. J Trauma 58:437–445
- Hill GE, Frawley WH, Griffith KE, Forestner JE, Minei JP (2003)
   Allogeneic blood transfusion increases the risk of postoperative bacterial infection: a meta-analysis. J Trauma 54:908–914
- McIntyre L, Hebert PC, Wells G, Fergusson D, Marshall J, Yetisir E, Blajchman MJ; Canadian Critical Care Trials Group (2004) Is a restrictive transfusion strategy safe for resuscitated and critically ill trauma patients? J Trauma 57:563–568
- Vincent JL, Baron JF, Reinhart K, Gattinoni L, Thijs L, Webb A, Meier-Hellmann A, Nollet G, Peres-Bota D; ABC (Anemia, Blood Transfusion in Critical Care) Investigators (2002) Anemia and blood transfusion in critically ill patients. JAMA 288: 1499–1507
- Corwin HL, Gettinger A, Pearl RG, Fink MP, Levy MM, Abraham E, MacIntyre NR, Shabot MM, Duh MS, Shapiro MJ (2004)
   The CRIT Study: anemia and blood transfusion in the critically ill—current clinical practice in the United States. Crit Care Med 32:39–52
- Shapiro MJ, Gettinger A, Corwin HL, Napolitano L, Levy M, Abraham E, Fink MP, MacIntyre N, Pearl RG, Shabot MM (2003) Anemia and blood transfusion in trauma patients admitted to the intensive care unit. J Trauma 55:269–274

